TG THERAPEUTICS INC (NASDAQ:TGTX) Shows High Growth Momentum and Technical Breakout Setup

Investors looking for high-growth momentum chances often search for companies showing firm earnings speed-up, good analyst changes, and growing profit edges, mixed with positive technical formations. The ChartMill High Growth Momentum Rating brings these basic growth parts into one number, while the Technical Rating and Setup Quality Score judge a stock's trend force and base shapes. This many-sided method aids in finding securities set for possible breakout moves.

Growth Momentum Basics

TG THERAPEUTICS INC (NASDAQ:TGTX) displays interesting growth traits that add to its High Growth Momentum Rating of 7. The company's recent quarterly report shows notable speed-up in both earnings and sales, which are main parts of the momentum rating method.

• Quarterly EPS growth jumped 325% measured against the same quarter last year, after earlier quarters showing 142.9% and 250% growth
• Sales rose 92.1% year-over-year in the latest quarter, keeping firm momentum from earlier times
• Next quarter guesses show outstanding 1,047.5% EPS growth and 85% sales growth
• Full-year EPS growth hit 1,300% in the most recent fiscal year
• The company passed sales guesses in three of the last four quarters

These numbers show the earnings speed-up and sales growth that high growth momentum investors focus on. The growing profit edges, which got better from 4.6% to 20% in recent quarters, add more support to the investment idea for momentum plans.

Technical Force and Market Place

The technical study shows outstanding force in TG Therapeutics' price movement. The stock gets a full Technical Rating of 10, showing firm results across both short and long-term periods.

• Both short-term and long-term directions stay positive
• The stock does better than 86% of all stocks on a yearly results basis
• Relative force inside the biotechnology field shows it does better than 72% of similar companies
• The stock is now making a bull flag shape, hinting at possible follow-on of the upward direction
• Volume traits show much lower action during recent dips, pointing to healthy base building

The technical picture matches the wider market situation where the S&P 500 keeps positive short and long-term directions, giving a supportive setting for breakout formations.

Setup Quality and Trading Points

With a Setup Rating of 7, TG Therapeutics shows a positive base shape for possible entry. The technical report points to lower price swings and a dip that may give planned entry spots.

• Five clear support areas give many layers for risk control
• Block sits tightly between $36.77 and $36.84, making a clear breakout point
• The setup hints at an entry at $36.85 with an exit at $36.07, holding risk to about 2.12%
• Large player action has shown recent notice, adding belief to the setup

The mix of tight base building near block with many support layers below makes the kind of risk-reward situation that technical breakout investors look for. The full technical analysis report gives more details on specific support and block changes.

Investment Meaning

For investors using high growth momentum plans, TG Therapeutics stands as an interesting case where firm basic growth numbers meet positive technical placing. The company's sharp earnings speed-up and sales growth give the basic driver, while the technical setup gives a set risk frame for entry.

The meeting of these parts, outstanding EPS growth, growing profit edges, full technical rating, and helpful base shape, makes a situation worth notice for momentum-centered investors. The stock shows how the ChartMill rating method can find securities fitting many needs important for breakout investing.

For investors looking for more chances with like traits, the High Growth Momentum Breakout Setups screen gives often fresh results filtering for stocks with firm growth momentum and technical formations.

,

Disclaimer: This study is for information only and does not make up investment guidance, suggestion, or backing of any security. Investors should do their own study and talk with a skilled money helper before making investment choices. Past results do not promise future outcomes.